Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002 Dec 15;100(13):4671-5 PMID: 12393648

Pubmed ID



In this study, we evaluated the prognostic significance of multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4) expression in B-cell chronic lymphocytic leukemia (B-CLL). Our results demonstrated that the absence of MUM1/IRF4 expression showed the highest relative risk among the factors analyzed in determining the probability for death in patients with B-CLL using univariate and multivariate Cox regression analysis. Patients without MUM1/IRF4 expression had significantly worse overall survival than did those with MUM1/IRF4 expression (52% cumulative survival, 63 months vs not reached, Kaplan-Meier survival analysis; P <.03, log-rank test). Patients with MUM1/IRF4 expression were more likely to have disease at low Rai stage and interstitial/nodular marrow involvement. Furthermore, only 1 of 11 patients with MUM1/IRF4 expression and interstitial/nodular marrow involvement died during a 100-month follow-up. Our results suggest that B-CLL with expression of MUM1/IRF4, indicative of postgerminal center origin, has a more favorable clinical course and that MUM1/IRF4 is an important prognostic marker in B-CLL.

Author List

Chang CC, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B, Kampalath B, Cleveland RP


Christopher R. Chitambar MD Professor in the Medicine department at Medical College of Wisconsin
Brent R. Logan PhD Director, Professor in the Institute for Health and Equity department at Medical College of Wisconsin


2-s2.0-0037114759   45 Citations

MESH terms used to index this publication - Major topics in bold

Biomarkers, Tumor
DNA-Binding Proteins
Follow-Up Studies
Gene Rearrangement, B-Lymphocyte, Heavy Chain
Genes, Immunoglobulin
Interferon Regulatory Factors
Leukemia, Lymphocytic, Chronic, B-Cell
Life Tables
Middle Aged
Multivariate Analysis
Neoplasm Proteins
Proportional Hazards Models
Survival Analysis
Transcription Factors
Treatment Outcome
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70